Skip to Content

HilleVax Inc HLVX

Morningstar Rating
$13.01 −0.90 (6.47%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

HLVX is trading at a 54% discount.
Price
$13.96
Fair Value
$38.32
Uncertainty
Extreme
1-Star Price
$342.66
5-Star Price
$7.96
Economic Moat
Zdgl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HLVX is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$13.91
Day Range
$12.9913.79
52-Week Range
$9.9420.22
Bid/Ask
$5.22 / $13.04
Market Cap
$646.61 Mil
Volume/Avg
52,535 / 136,656

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees
90

Comparables

Valuation

Metric
HLVX
ICVX
PCVX
Price/Earnings (Normalized)
Price/Book Value
2.523.304.81
Price/Sales
Price/Cash Flow
Price/Earnings
HLVX
ICVX
PCVX

Financial Strength

Metric
HLVX
ICVX
PCVX
Quick Ratio
10.3717.597.43
Current Ratio
10.6218.067.54
Interest Coverage
−54.72
Quick Ratio
HLVX
ICVX
PCVX

Profitability

Metric
HLVX
ICVX
PCVX
Return on Assets (Normalized)
−34.03%−29.30%−21.69%
Return on Equity (Normalized)
−42.52%−31.87%−23.31%
Return on Invested Capital (Normalized)
−38.62%−34.69%−28.13%
Return on Assets
HLVX
ICVX
PCVX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXwjqclsmhDbh$559.8 Bil
VRTX
Vertex Pharmaceuticals IncXpmszvqtlKhjdk$102.5 Bil
REGN
Regeneron Pharmaceuticals IncTqlsvfzfpVdbdfm$98.6 Bil
MRNA
Moderna IncWmkkhdpkLytp$41.0 Bil
ARGX
argenx SE ADRTkqdljlgHvscn$22.6 Bil
BNTX
BioNTech SE ADRPbsqzbnrDdl$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncYxzjgnjrZckwlv$18.8 Bil
BMRN
Biomarin Pharmaceutical IncJvnbxmfnfKjtwcj$17.4 Bil
RPRX
Royalty Pharma PLC Class ATnzvxtrvnDwkvkk$12.6 Bil
INCY
Incyte CorpDfjyctvvWrtmqd$12.0 Bil

Sponsor Center